Sorrento Therapeutics, Inc. (SRNE)

Oncology Corporate Profile

Stock Performance

6.9200
-0.2700

HQ Location

6042 Cornerstone Ct. West, Suite B
San Diego, CA 92121

Company Description

Sorrento is an oncology company developing new treatments for cancer and its associated pain. Sorrento's most advanced asset Cynviloq, the next-generation paclitaxel, commenced its registrational trial on March 31, 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opioid TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain.

Website: http://sorrentotherapeutics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
cynviloqmonoclonal antibodyBreast CancerIII
cynviloqmonoclonal antibodyNon Small Cell Lung Cancer (NSCLC)III
cynviloqmonoclonal antibodyBladder cancerII
cynviloqmonoclonal antibodyOvarian cancerII
cynviloqmonoclonal antibodyPancreatic CancerII

View additional information on product candidates here »

Source: http://sorrentotherapeutics.com

Recent News Headlines

7/20/2017 06:19 pm

7/20/2017 06:19 pm

7/20/2017 06:19 pm

7/17/2017 06:19 am

7/17/2017 06:19 am

7/17/2017 06:19 am

6/30/2017 12:19 pm

6/30/2017 12:19 pm

6/29/2017 12:19 pm

6/29/2017 12:19 pm

6/29/2017 06:19 am

6/29/2017 06:19 am

6/29/2017 06:19 am

6/26/2017 12:20 am

6/26/2017 12:20 am

6/26/2017 12:20 am

6/14/2017 12:19 pm

6/14/2017 06:19 am

6/13/2017 06:19 am

5/4/2017 06:19 am

5/2/2017 12:19 pm

4/28/2017 06:19 am

4/19/2017 12:19 pm

4/19/2017 12:19 pm

4/10/2017 12:17 pm